They act on completely different receptor pathways to produce the same end result (growth hormone release)
[Updated 2024 Feb 29].Treasure Island 8.Vozza A, Triggiani D, Fanelli M, Lisco G, Coletto D, Custodero C, Volpe S, Racaniello D, Colaianni V, Lavarra V, Maggipinto R, Portacci A, Tortorella C, Moschetta A and Piazzolla G (2025) Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study.Front
When Novo Nordisks parent holding company bought it in March 2024, they essentially took a massive piece of global fill-finish manufacturing capacity off the open market and locked it exclusively for Novo products
None of the content in this post should be taken as medical advice
She was initially on liraglutide (Saxenda) at a dose of up to 3 mg daily for six months without issue